Alectinib (Alecensa®). HTA ID: 24017

Assessment Status Rapid Review complete
HTA ID 24017
Drug Alectinib
Brand Alecensa®
Indication As adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence.
Assessment Process
Rapid review commissioned 24/05/2024
Rapid review completed 02/07/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alectinib for this indication compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies.